Inoviq Ltd
Research Inoviq Ltd (IIQ) on Bullrun: market cap AUD 20.41M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIIQ
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyAUD
- Market capAUD 20.41M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 20.41M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.06 | n/a | n/a | n/a |
| FY2024 | AUD 535.12K | -AUD 6.55M | -AUD 4.50M | 84.9% | -0.07 | AUD 9.23M | AUD 403.74K | AUD 19.99M |
| FY2023 | AUD 398.19K | -AUD 8.97M | -AUD 7.32M | 88.8% | -0.1 | AUD 7.81M | AUD 730.71K | AUD 19.62M |
| FY2022 | AUD 276.75K | -AUD 18.20M | -AUD 6.47M | 79.6% | -0.07 | AUD 15.39M | AUD 998.69K | AUD 28.29M |
| FY2021 | AUD 468.10K | -AUD 12.37M | -AUD 6.05M | 86.3% | n/a | AUD 9.02M | AUD 1.26M | AUD 27.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-14 | AUD 20.41M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Inoviq Ltd's market cap?
Inoviq Ltd's market capitalization is AUD 20.41M.
What does Inoviq Ltd do?
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium.